Form 4: Skye Bioscience Director Acquires 70,000 Stock Options
SEC Form 4 Filing
Director Andrew J. Schwab acquired 70,000 stock options in Skye Bioscience, Inc. on October 28, 2024.
Summary
- Andrew J. Schwab, a director of Skye Bioscience, Inc., acquired 70,000 stock options on October 28, 2024.
- The options have an exercise price of $5.15.
- The options vest in equal monthly installments over one year, starting October 28, 2024.
- The options expire on October 27, 2034.
- Following the transaction, Schwab directly owns 70,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't convey any explicit positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders, allowing investors to monitor their investment decisions.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 10/28/2024 | Date of earliest transaction: Director acquired 70,000 stock options. |
| 10/28/2024 | Vesting start date: Stock options vest in equal monthly installments over one year. |
| 10/27/2034 | Expiration date: Stock options expire. |
| 10/30/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.